Literature DB >> 28448739

Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.

Xiaoqing Cheng1,2, Yueyuan Zhao3, Xuefeng Zhang4, Hui Jin1,2, Jie Min1.   

Abstract

Objective This study was conducted to assess the cost-effectiveness of hepatitis E vaccination of elderly population in the sporadic regions in China. Methods We used a decision tree-Markov model to evaluate the cost-effectiveness of 3 kinds of hepatitis E virus vaccination strategies from societal perspectives. Parameter estimates were obtained from published researches and experts' opinion. The time horizon was 16 years, and the discounted rate was 3% annually. Costs are expressed in 2016 US dollars. Results The universal vaccination strategy had an incremental cost-effectiveness ratio (ICER) of US$ 8475.90 per QALY gained versus no vaccination. The implementation of screening and vaccination strategy would have an ICER of US$ 4044.28, compared with no vaccination. The vaccination was cost-effective (ICER< 3 times China's per capital gross domestic product/quality-adjusted life years). The QALY of asymptomatic infection, vaccine coverage and vaccine protection are the important parameters impacting the ICER in one-way sensitivity analysis and screening and vaccination being the dominant strategy in probabilistic sensitivity analysis. Conclusion This analysis indicates that screening and vaccination is the most cost-effective hepatitis E intervention strategy of elderly population in sporadic region in China.

Entities:  

Keywords:  Cost-effectiveness analysis; Economic evaluation; Elderly population; Hepatitis E vaccines

Mesh:

Substances:

Year:  2017        PMID: 28448739      PMCID: PMC5557228          DOI: 10.1080/21645515.2017.1316913

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  23 in total

1.  Forecasting the economic value of an Enterovirus 71 (EV71) vaccine.

Authors:  Bruce Y Lee; Angela R Wateska; Rachel R Bailey; Julie H Y Tai; Kristina M Bacon; Kenneth J Smith
Journal:  Vaccine       Date:  2010-10-16       Impact factor: 3.641

2.  Modelling in the economic evaluation of health care: selecting the appropriate approach.

Authors:  Pelham Barton; Stirling Bryan; Suzanne Robinson
Journal:  J Health Serv Res Policy       Date:  2004-04

3.  Making hepatitis E a vaccine-preventable disease.

Authors:  Eyasu Teshale; John W Ward
Journal:  N Engl J Med       Date:  2015-03-05       Impact factor: 91.245

4.  [Epidemiologic and genetic characteristics of hepatitis E virus in Shanghai, 1997-2012].

Authors:  Hong Ren; Yan-ting Li; Xin Zhou; Ye Wang; Ying-jie Zheng; Yi-yi Zhu; Yi-han Lu
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2013-05

5.  Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.

Authors:  Man-Kit Leung; Joyce H S You
Journal:  Vaccine       Date:  2016-04-11       Impact factor: 3.641

Review 6.  The development of a recombinant hepatitis E vaccine HEV 239.

Authors:  Shao-Wei Li; Qinjian Zhao; Ting Wu; Shu Chen; Jun Zhang; Ning-Shao Xia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Hepatitis E vaccine development: a 14 year odyssey.

Authors:  Ting Wu; Shao-Wei Li; Jun Zhang; Mun-Hon Ng; Ning-Shao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2012-06-01       Impact factor: 3.452

Review 8.  Hepatitis E: an emerging awareness of an old disease.

Authors:  R H Purcell; S U Emerson
Journal:  J Hepatol       Date:  2008-01-02       Impact factor: 25.083

9.  Partial nucleotide sequencing of hepatitis E viruses detected in sera of patients with hepatitis E from 14 cities in China.

Authors:  Kui Li; Hui Zhuang; Wanfu Zhu
Journal:  Chin Med J (Engl)       Date:  2002-07       Impact factor: 2.628

10.  Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in China.

Authors:  Feng-Cai Zhu; Shou-Jie Huang; Ting Wu; Xue-Feng Zhang; Zhong-Ze Wang; Xing Ai; Qiang Yan; Chang-Lin Yang; Jia-Ping Cai; Han-Min Jiang; Yi-Jun Wang; Mun-Hon Ng; Jun Zhang; Ning-Shao Xia
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

View more
  3 in total

1.  Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.

Authors:  Ira L Leeds; Vasanthkumar Namasivayam; Assanatou Bamogo; Prithvi Sankhla; Winter M Thayer
Journal:  Am J Prev Med       Date:  2018-12-17       Impact factor: 5.043

Review 2.  [Vaccines against hepatitis E virus: state of development].

Authors:  Patrick Behrendt; Heiner Wedemeyer
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-01-31       Impact factor: 1.513

Review 3.  Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis.

Authors:  Nicolas Iragorri; Eldon Spackman
Journal:  Public Health Rev       Date:  2018-07-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.